Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

Johnson & Johnson (JNJ) is a prominent healthcare conglomerate, headquartered in New Brunswick, New Jersey, boasting a diversified portfolio encompassing prescription medicines and advanced medical technologies. With a market capitalization of $640.5 billion, JNJ is classified as a mega-cap stock. The company operates under two primary segments: Innovative Medicine and MedTech.

The consumer staples sector, which JNJ operates within, is also experiencing growth, as evidenced by the State Street Consumer Staples Select Sector SPDR Fund (XLP) which has risen 1.2% over the past three months. JNJ's performance has been particularly strong, trading 3.1% below its 52-week high of $276.47, reached on August 19.

Over the past year, JNJ has surged 52.8%, significantly outpacing the XLP's 6.5% growth. The company's stock has consistently remained above its 50-day and 200-day moving averages, signaling an ongoing uptrend. JNJ's recent strong earnings report for the second quarter of 2026, combined with its robust outlook, has renewed investor enthusiasm.

The company's sales grew by 6.6% year-over-year, reaching $25.31 billion, with adjusted earnings-per-share (EPS) hitting $2.90, surpassing market expectations. Furthermore, JNJ has raised its 2026 earnings guidance, projecting sales of $101.1 billion and an adjusted EPS of $11.58. When compared to its competitor Eli Lilly and Company (LLY), which has gained 60.5% over the past year, JNJ has underperformed.

Analysts covering JNJ maintain a moderately optimistic consensus rating of "Moderate Buy," with a mean price target of $276.29, suggesting a 3.1% upside potential from the current stock price.